GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Inclusion Criteria:

• Albuminuria defined as urinary albumin:creatinine ratio ≥ 25 mg/g (orprotein:creatinine ratio ≥ 30 mg/g) or albuminuria > 30 mg/24h

• eGFR > 25 and < 75 ml/minute 1.73m2

• BMI between 19 kg/m2 and 30 kg/m2

• Treatment with an ACE inhibitor and/or ARB at the maximum tolerated (for theindividual subject) dose. The maximum tolerated dose for an individual subject maybe less than the maximum labeled dose or may be zero if the medical reason isdocumented.

• Mean systolic and diastolic blood pressure (determined as the average of threereplicates) must be < 180/90mmHg

• Pre-menopausal women of child-bearing potential 1 must have a negative pregnancytest performed before the inclusion in the study V e r s i o n 6 . 0 - P a g . 10 | 32

• Willingness to participate in the study (signed informed consent)

IN PARTICIPANTS WITH Type 2 Diabetes

• Clinical diagnosis of T2DM for at least 1 year

• Hemoglobin A1c (HbA1c) value of < 9.5%

• Patients treated only with metformin and/or repaglinide

• A diagnosis of Diabetic Nephropathy at renal biopsy made not more than 6 monthsbefore the screening visit (only for the subgroup of patients candidated to thesecond kidney biopsy)

• Proteinuria > 1g/24h (only for the subgroup of patients candidated to the secondkidney biopsy)

• Hemoglobin A1c (HbA1c) value of > 6.5% (only for patients candidated to the secondkidney biopsy) In PARTICIPANTS Without Type 2 Diabetes

• diagnosis of hypertension for at least 5 years

Exclusion Criteria:

• Type 1 Diabetes

• Hemoglobin A1c (HbA1c) value of > 9.5% during the Screening period (based on centrallaboratory measurement).

• The need for an adjunctive drugs on top on metformin and repaglinide

• Hemoglobin A1c (HbA1c) value of < 6.5% only for patients candidated to the secondkidney biopsy

• Estimated glomerular filtration rate < 25 or > 75 ml/min/1.73m2 (according to theCKD-EPI) at screening

• Untreated urinary or genital infection at screening and follow-up

• Clear signs of volume depletion

• Symptomatic hypotension, or systolic blood pressure < 90 or non-controlledhypertension

• History of alcohol or drug abuse, anuria, dialysis, or acute kidney injury/acuterenal failure in the 3 months prior to Screening Period

• Heart, liver or kidney transplant V e r s i o n 6 . 0 - P a g . 11 | 32

• Acute coronary syndrome, stroke, or transient ischemic attack within 3 months priorto informed consent

• Liver disease, defined by serum levels of alanine aminotransferase, aspartateaminotransferase, or alkaline phosphatase above 3 x upper limit of normal (ULN)during screening

• Planned cardiac surgery or angioplasty within 3 months

• Cancer or medical history of cancer (except for basal cell carcinoma) within thelast 5 years

• Treatment with anti-obesity drugs 3 months prior to informed consent or any othertreatment at time of screening leading to unstable body weight (e.g. surgery,aggressive diet regimen, etc.)

• SGLT2i treatment in the 10 weeks before the Screening Period

• Treatment with systemic steroids at time of informed consent or change in dosage ofthyroid hormones within 6 weeks prior to informed consent

• Any uncontrolled endocrine disorder except T2DM

• Women who are pregnant or breastfeeding

• Pre-menopausal women of child bearing potential who are not willing to employeffective contraception according to 2007 CTFG Recommendations related tocontraception and pregnancy testing in clinical trials from screening for all theduration of the study

• Patients with a known hypersensitivity to Dapagliflozin or other SGLT2- inhibitors,including hypersensitivity to excipients (e.g. lactose)

• History of pancreatitis, or pancreatic surgery, diabetic ketoacidosis

• Prior lower extremity amputation or current threat of amputation (eg, lowerextremity ulcer and peripheral artery disease)

• History of severe hypoglycaemia and hypoglycaemia unawareness.

• Contraindication to MRI